Nutraceticals for dissolving nephrolites in cats

ABSTRACT

Background: Nephrolithiasis is a condition frequently observed in felines, with or without concomitant chronic kidneydisease, constituting the major cause of ureteral obstruction and causing progressive damage to the renal parenchyma. About90% of nephrolites are composed of calcium oxalate, which cannot dissolve, and its incidence has increased substantiallyin recent years, along with its recurrence. There are functional foods known as nutraceuticals provides health benefits suchas renoprotection. Due to these benefits and the high prevalence of nephrolithiasis in feline species, the present study aimedto evaluate the efficacy of the association of some nutraceuticals in the dissolution of nephrolites.Materials, Methods & Results: The included cats had an ultrasound diagnosis of nephrolithiasis that, on clinical examination, showed (i) the absence of previous or concomitant treatment for urinary infections and/or vesical and renal lithiasis;(ii) absence of genitourinary clinical manifestations; (iii) absence of obstructive processes; and (iv) absence of concomitantureterolithiasis. We separated 51 cats with nephrolithiasis into 2 groups control (n = 12) and study (n = 39). The controlgroup received a placebo and the study group, nutraceuticals (magnesium chelate, resveratrol, vitamin K2, docosahexaenoicacid, and eicosapentaenoic acid). Laboratory tests (blood and urine) and abdominal imaging (ultrasound) were performedat day 0 and 30 days after enrollment. Monitoring the therapeutic efficacy in both groups was performed on day 30 for theCG and on days 30, 60, and 90 for the EG. The CG cats, after this step, were referred to surgery or to the EG, with priorauthorization from their tutors. The diameter of nephrolites was significantly different before and after treatment, indicating a reduction in nephroliths over time. During the use of the nutraceutical formulation by the EG and use of placebo...